USE OF N-ACETYLCYSTEINE IN CLINICAL TOXICOLOGY

被引:108
作者
FLANAGAN, RJ [1 ]
MEREDITH, TJ [1 ]
机构
[1] DEPT HLTH,DIV TOXICOL & ENVIRONM HLTH,LONDON,ENGLAND
关键词
D O I
10.1016/0002-9343(91)90296-A
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The major use of N-acetylcysteine in clinical toxicology is in the treatment of acetaminophen (paracetamol) overdosage. The hepatorenal toxicity of acetaminophen is mediated by a reactive metabolite normally detoxified by reduced glutathione. If glutathione is depleted, covalent binding to macromolecules and/or oxidation of thiol enzymes can lead to cell death. Oral or intravenous N-acetylcysteine or oral D,L-methionine mitigates acetaminophen-induced hepatorenal damage if given within 10 hours, but becomes less effective thereafter. In vivo, N-acetylcysteine forms L-cysteine, cystine, L-methionine, glutathione, and mixed disulfides; L-methionine also forms cysteine, thus giving rise to glutathione and other products. Oral therapy with N-acetylcysteine or methionine for acetaminophen poisoning is contraindicated in the presence of coma or vomiting, or if activated charcoal has been given by mouth. Nausea, vomiting, and diarrhea may also occur as a result of oral N-acetylcysteine administration. Anaphylactoid reactions including angio-edema, bronchospasm, flushing, hypotension, nausea/vomiting, rash, tachycardia, and respiratory distress may occur 15-60 minutes into N-acetylcysteine infusion (20 hour intravenous regimen) in up to 10% of patients. Following accidental intravenous overdosage, the adverse reactions of N-acetylcysteine are similar but more severe; fatalities have occurred. A reduction in the loading dose of N-acetylcysteine may reduce the risk of adverse reactions while maintaining efficacy. Administration of N-acetylcysteine for a longer period might provide enhanced protection for patients in whom acetaminophen absorption or elimination is delayed. N-acetylcysteine may also have a role in the treatment of toxicity from carbon tetrachloride, chloroform, 1,2-dichloropropane, and other compounds. The possible use of N-acetyl-cysteine and other agents in the prevention of the neuropsychiatric sequelae of acute carbon monoxide poisoning is an important area for future research.
引用
收藏
页码:S131 / S139
页数:9
相关论文
共 74 条
  • [1] DMSA AND DMPS - WATER-SOLUBLE ANTIDOTES FOR HEAVY-METAL POISONING
    APOSHIAN, HV
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1983, 23 : 193 - 215
  • [2] BAILEY DJ, 1987, PEDIATRICS, V79, P281
  • [3] DELAYED ACETAMINOPHEN TOXICITY DESPITE ACETYLCYSTEINE USE
    BARTLE, WR
    PARADISO, FL
    DERRY, JE
    LIVINGSTONE, DJ
    [J]. DICP-THE ANNALS OF PHARMACOTHERAPY, 1989, 23 (06): : 509 - 509
  • [4] ADVERSE REACTIONS TO N-ACETYLCYSTEINE
    BATEMAN, DN
    WOODHOUSE, KW
    RAWLINS, MD
    [J]. HUMAN TOXICOLOGY, 1984, 3 (05): : 393 - 398
  • [5] ACUTE ACRYLONITRILE TOXICITY - STUDIES ON THE MECHANISM OF THE ANTIDOTAL EFFECT OF D-CYSTEINE AND L-CYSTEINE AND THEIR N-ACETYL DERIVATIVES IN THE RAT
    BENZ, FW
    NERLAND, DE
    PIERCE, WM
    BABIUK, C
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 1990, 102 (01) : 142 - 150
  • [6] PHARMACOKINETICS OF N-ACETYLCYSTEINE IN MAN
    BORGSTROM, L
    KAGEDAL, B
    PAULSEN, O
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (02) : 217 - 222
  • [7] BOYD JA, 1981, J PHARMACOL EXP THER, V219, P659
  • [8] BRONSTEIN AC, 1985, VET HUM TOXICOL, V27, P316
  • [9] BRUNO MK, 1988, BIOCHEM PHARMACOL, V37, P4319
  • [10] BUCKPITT AR, 1983, J PHARMACOL EXP THER, V225, P8